[1]
|
Grothey, A. and Goldberg, R.M. (2004) A Review of Oxaliplatin and Its Clinical Use in Colorectal Cancer. Expert Opinion on Pharmacotherapy, 5, 2159-2170.
http://dx.doi.org/10.1517/14656566.5.10.2159
|
[2]
|
Rixe, O., Ortuzar, W., Alvarez, M., et al. (1996) Oxaliplatin, Tetraplatin, Cisplatin, and Carboplatin: Spectrum of Activity in Drug-Resistant Cell Lines and in the Cell Lines of the National Cancer Institute’s Anticancer Drug Screen Panel. Biochemical Pharmacology, 52, 1855-1865. http://dx.doi.org/10.1016/S0006-2952(97)81490-6
|
[3]
|
de Gramont, A., Figer, A., Seymour, M., et al. (2000) Leucovorin and Fluorouracil with or without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. Journal of Clinical Oncology, 18, 2938-2947.
|
[4]
|
Maindrault-Goebel, F., Louvet, C., Andre, T., et al. (1999) Oxaliplatin Added to the Simplified Bimonthly Leucovorin and 5-Fluorouracil Regimen as Second-Line Therapy for Metastatic Colorectal Cancer (FOLFOX6). GERCOR. European Journal of Cancer, 35, 1338-1342.
http://dx.doi.org/10.1016/S0959-8049(99)00149-5
|
[5]
|
Alberts, S.R., Horvath, W.L., Sternfeld, W.C., et al. (2005) Oxaliplatin, Fluorouracil, and Leucovorin for Patients with Unresectable Liver-Only Metastases from Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study. Journal of Clinical Oncology, 23, 9243-9249. http://dx.doi.org/10.1200/JCO.2005.07.740
|
[6]
|
Andre, T., Boni, C., Mounedji-Boudiaf, L, et al. (2004) Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. New England Journal of Medicine, 350, 2343-2351. http://dx.doi.org/10.1056/NEJMoa032709
|
[7]
|
Cassidy, J., Tabernero, J., Twelves, C., et al. (2004) XELOX (Capecitabine plus Oxaliplatin): Active First-Line Therapy for Patients with Metastatic Colorectal Cancer. Journal of Clinical Oncology, 22, 2084-2091. http://dx.doi.org/10.1200/JCO.2004.11.069
|
[8]
|
Tournigand, C., Cervantes, A., Figer, A., et al. (2006) OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 with Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study. Journal of Clinical Oncology, 24, 394-400.
http://dx.doi.org/10.1200/JCO.2005.03.0106
|
[9]
|
Wilson, R.H., Lehky, T., Thomas, R.R., et al. (2002) Acute Oxaliplatin-Induced Peripheral Nerve Hyperexcitability. Journal of Clinical Oncology, 20, 1767-1774.
http://dx.doi.org/10.1200/JCO.2002.07.056
|
[10]
|
Adelsberger, H., Quasthoff, S., Grosskreutz, J., Lepier, A., Eckel, F. and Lersch, C. (2000) The Chemotherapeutic Oxaliplatin Alters Voltage-Gated Na(+) Channel Kinetics on Rat Sensory Neurons. European Journal of Pharmacology, 406, 25-32.
http://dx.doi.org/10.1016/S0014-2999(00)00667-1
|
[11]
|
Grolleau, F., Gamelin, L., Boisdron-Celle, M., Lapied, B., Pelhate, M. and Gamelin, E. (2001) A Possible Explanation for a Neurotoxic Effect of the Anticancer Agent Oxaliplatin on Neuronal Voltagegated Sodium Channels. Journal of Neurophysiology, 85, 2293-2297.
|
[12]
|
Gamelin, L., Capitain, O., Morel, A., et al. (2007) Predictive Factors of Oxaliplatin Neurotoxicity: The Involvement of the Oxalate Outcome Pathway. Clinical Cancer Research, 13, 6359-6368. http://dx.doi.org/10.1158/1078-0432.CCR-07-0660
|
[13]
|
Extra, J.M., Marty, M., Brienza, S., et al. (1998) Pharmacokinetics and Safety Profile of Oxaliplatin. Seminars in Oncology, 25, 13-22.
|
[14]
|
Gamelin, L., Boisdron-Celle, M., Delva, R., et al. (2004) Prevention of Oxaliplatin-Related Neurotoxicity by Calcium and Magnesium Infusions: A Retrospective Study of 161 Patients Receiving Oxaliplatin Combined with 5-Fluorouracil and Leucovorin for Advanced Colorectal Cancer. Clinical Cancer Research, 10, 4055-4061.
http://dx.doi.org/10.1158/1078-0432.CCR-03-0666
|
[15]
|
Lersch, C., Schmelz, R., Eckel, F., et al. (2002) Prevention of Oxaliplatin-Induced Peripheral Sensory Neuropathy by Carbamazepine in Patients with Advanced Colorectal Cancer. Clinical Cancer Research, 2, 54-58. http://dx.doi.org/10.3816/ccc.2002.n.011
|
[16]
|
Penz, M., Kornek, G.V., Raderer, M., et al. (2001) Subcutaneous Administration of Amifostine: A Promising Therapeutic Option in Patients with Oxaliplatin-Related Peripheral Sensitive Neuropathy. Annals of Oncology, 12, 421-422.
http://dx.doi.org/10.1023/A:1011184609963
|
[17]
|
Cascinu, S., Catalano, V., Cordella, L., et al. (2002) Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Oncology, 20, 3478-3483. http://dx.doi.org/10.1200/JCO.2002.07.061
|
[18]
|
Bergstrom, J., Furst, P., Noree, L.O. and Vinnars, E. (1974) Intracellular Free Amino Acid Concentration in Human Muscle Tissue. Journal of Applied Physiology, 36, 693-697.
|
[19]
|
Savarese, D.M., Savy, G., Vahdat, L., et al. (2003) Prevention of Chemotherapy and Radiation Toxicity with Glutamine. Cancer Treatment Reviews, 29, 501-513.
http://dx.doi.org/10.1016/S0305-7372(03)00133-6
|
[20]
|
Lacey, J.M. and Wilmore, D.W. (1990) Is Glutamine a Conditionally Essential Amino Acid? Nutrition Reviews, 48, 297-309. http://dx.doi.org/10.1111/j.1753-4887.1990.tb02967.x
|
[21]
|
Bartlett, D.L., Charland, S. and Torosian, M.H. (1995) Effect of Glutamine on Tumor and Host Growth. Annals of Surgical Oncology, 2, 71-76. http://dx.doi.org/10.1007/bf02303705
|
[22]
|
Vahdat, L., Papadopoulos, K., Lange, D., et al. (2001) Reduction of Paclitaxel-Induced Peripheral Neuropathy with Glutamine. Clinical Cancer Research, 7, 1192-1197.
|
[23]
|
De Santis, S., Pace, A., Bove, L., et al. (2000) Patients Treated with Antitumor Drugs Displaying Neurological Deficits Are Characterized by a Low Circulating Level of Nerve Growth Factor. Clinical Cancer Research, 6, 90-95.
|
[24]
|
Apfel, S.C., Lipton, R.B., Arezzo, J.C. and Kessler, J.A. (1991) Nerve Growth Factor Prevents Toxic Neuropathy in Mice. Annals of Neurology, 29, 87-90.
http://dx.doi.org/10.1002/ana.410290115
|
[25]
|
Gwag, B.J., Sessler, F.M., Robine, V. and Springer, J.E. (1997) Endogenous Glutamate Levels Regulate Nerve Growth Factor mRNA Expression in the Rat Dentate Gyrus. Molecules and Cells, 7, 425-430.
|
[26]
|
Daikhin, Y. and Yudkoff, M. (2000) Compartmentation of Brain Glutamate Metabolism in Neurons and Glia. Journal of Nutrition, 130, 1026-1031S.
www.ncbi.nlm.nih.gov/pubmed/10736375
|
[27]
|
Cardona Pera, D. (1998) Administration of Glutamine and Its Dipeptides in Parenteral Nutrition. Which Patients Are Candidates? Nutrición Hospitalaria, 13, 8-20.
http://www.ncbi.nlm.nih.gov/pubmed/9578682
|
[28]
|
Hochster, H., Chachoua, A., Speyer, J., Zeleniuch-Jacquotte, A. and Muggia, F. (2003) Oxaliplatin with Weekly Bolus Fluorouracil and Low-Dose Leucovorin as First-Line Therapy for Patients with Colorectal Cancer. Journal of Clinical Oncology, 21, 2703-2707.
http://dx.doi.org/10.1200/JCO.2003.02.071
|
[29]
|
Ziegler, T.R. (2002) Glutamine Supplementation in Bone Marrow Transplantation. British Journal of Nutrition, 87, S9-S15. http://dx.doi.org/10.1079/bjn2001452
|
[30]
|
Cao, Y., Kennedy, R. and Klimberg, V.S. (1999) Glutamine Protects against Doxorubicin-Induced Cardiotoxicity. Journal of Surgical Research, 85, 178-182.
http://dx.doi.org/10.1006/jsre.1999.5677
|
[31]
|
Boyle, F.M., Wheeler, H.R. and Shenfield, G. (1996) Glutamate Ameliorates Experimental Vincristine Neuropathy. Journal of Pharmacology and Experimental Therapeutics, 279, 410-415.
|
[32]
|
Boyle, F.M., Wheeler, H.R. and Shenfield, G.M. (1999) Amelioration of Experimental Cisplatin and Paclitaxel Neuropathy with Glutamate. Journal of Neuro-Oncology, 41, 107-116.
http://dx.doi.org/10.1023/A:1006124917643
|
[33]
|
Savarese, D., Boucher, J. and Corey, B. (1998) Glutamine Treatment of Paclitaxel-Induced Myalgias and Arthralgias. Journal of Clinical Oncology, 16, 3918-3919.
|
[34]
|
Wang, W.-S., Lin, J.-K., Lin, T.-C., Chen, W.-S., Jiang, J.-K., Wang, H.-S., Chiou, T.-J., Liu, J.-H., Yen, C.-C. and Chen, P.-M. (2007) Oral Glutamine Is Effective for Preventing Oxaliplatin-Induced Neuropathy in Colorectal Cancer Patients. The Oncologist, 12, 312-319.
http://dx.doi.org/10.1634/theoncologist.12-3-312
|
[35]
|
Krishnan, A.V., Goldstein, D., Friedlander, M. and Kiernan, M.C. (2005) Oxaliplatin-Induced Neurotoxicity and the Development of Neuropathy. Muscle & Nerve, 32, 51-60.
http://dx.doi.org/10.1002/mus.20340
|
[36]
|
Chance, W.T., Cao, L., Kim, M.W., Nelson, J.L. and Fischer, J.E. (1988) Reduction of Tumor Growth Following Treatment with a Glutamine Antimetabolite. Life Sciences, 42, 87-94.
http://dx.doi.org/10.1016/0024-3205(88)90627-3
|
[37]
|
Fahr, M.J., Kornbluth, J., Blossom, S., Schaeffer, R. and Kumberg, V.S. (1994) Glutamine Enhances Immunoregulation of Tumor Growth. Journal of Parenteral and Enteral Nutrition, 18, 471-476. http://dx.doi.org/10.1177/0148607194018006471
|
[38]
|
Lin, C.M., Abcouwer, S.F. and Souba, W.W. (1999) Effect of Dietary Glutamate on Chemotherapy-Induced Immunosuppression. Nutrition, 15, 687-696.
http://dx.doi.org/10.1016/S0899-9007(99)00153-7
|
[39]
|
Horig, H., Spagnoli, G.C., Filgueira, L., et al. (1993) Exogenous Glutamine Requirement Is Confined to Late Events of T Cell Activation. Journal of Cellular Biochemistry, 53, 343-351.
http://dx.doi.org/10.1002/jcb.240530412
|
[40]
|
Klimberg, V.S., Kornbluth, J., Cao, Y., et al. (1996) Glutamine Suppresses PGE2 Synthesis and Breast Cancer Growth. Journal of Surgical Research, 63, 293-297.
http://dx.doi.org/10.1006/jsre.1996.0263
|